DIOS HFVac3
Alternative Names: DIOS-HFVac3Latest Information Update: 19 Apr 2024
At a glance
- Originator DIOSynVax
- Class RNA vaccines; Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Ebola virus infections; Lassa fever; Marburg virus disease
Most Recent Events
- 02 Apr 2024 DIOSynVax has patent protection for DIOSynVax technology platform (DIOSynVax website, April 2024)
- 27 Mar 2024 Preclinical trials in Ebola virus infections (Prevention) in United Kingdom (unspecified route) before March 2024
- 27 Mar 2024 Preclinical trials in Lassa fever (Prevention) in United Kingdom (unspecified route) before March 2024